CEO of Clarametyx Biosciences.
Clarametyx Biosciences Initiates Phase 2a Trial for CMTX-101 in Cystic Fibrosis Patients
David Richards emphasized the therapy’s potential to enhance antibiotic effectiveness by targeting bacterial biofilms, a significant challenge in treatment.
Read More